ProCE Banner Activity

Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM

Slideset Download
Conference Coverage
An all-oral regimen of selinexor + pomalidomide + low-dose dexamethasone appears to be safe and highly active in patients with heavily pretreated MM, warranting further evaluation.

Released: December 13, 2019

Expiration: December 11, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company